First detection of VIM-4 metallo-β-lactamase-producing Escherichia coli in Russia

Shevchenko, Oksana; Mudrak, D.Y.; Skleenova, E.Yu.; Kozyreva, Varvara K.; Ilina, Elena N.; Ikryannikova, Larisa N.; Alexandrova, Irina; Сидоренко, С. В.; Edelstein, Mikhail V.

doi:10.1111/j.1469-0691.2012.03827.x

Cited by 23 publications

(13 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…While isolates carrying bla SPM have been reported to be endemic in Brazil, surprisingly, no isolates carrying bla SPM were detected in that country during the 3 years of this study (25). Multiple MBL-positive isolates were detected in Russia and Greece, and the prevalence and spread of MBL-positive organisms within and from these countries have been reported previously (18,(26)(27)(28). In this study, the large number of MBL-positive organisms isolated in Philippines, which included 5 different species of Enterobacteriaceae and P. aeruginosa carrying genes for all three MBL types, exceeded those in previous reports and might suggest a strong potential for further spread in diverse geographic regions (29,30).…”

Section: Discussionsupporting

confidence: 65%

Multiyear, Multinational Survey of the Incidence and Global Distribution of Metallo-β-Lactamase-Producing Enterobacteriaceae and Pseudomonas aeruginosa

Kazmierczak¹,

Rabine²,

Hackel³

et al. 2016

Antimicrob Agents Chemother

189

117

View full text Add to dashboard Cite

T he worldwide dissemination of Gram-negative bacteria producing extended-spectrum ␤-lactamases (ESBLs) in the late 20th century resulted in a dearth of treatment options and an increase in the therapeutic use of carbapenems (1, 2). In turn, reports of carbapenem-resistant and carbapenemase-producing bacteria became more frequent (3-5). One important group of carbapenemases of special concern is the metallo-␤-lactamases (MBLs). These enzymes belong to Ambler class B and require 1 or 2 zinc ions for enzyme activity (6). Many MBLs are chromosomally encoded in environmental bacteria or species that can act as opportunistic pathogens. However, a number of MBLs, including the NDM-type, IMP-type, and VIM-type MBLs, are plasmid encoded and readily transferable among clinically significant bacterial species, including Klebsiella pneumoniae and Escherichia coli (3). Notably, MBLs are often coproduced with Ambler class A and C serine ␤-lactamases, including ESBLs and AmpC enzymes (7).MBLs hydrolyze all ␤-lactams except monobactams, including aztreonam, and are not inhibited by any of the commercially available ␤-lactamase inhibitors. Although aztreonam is active against many Gram-negative bacteria, it is inactive against isolates that produce ESBLs, KPC carbapenemases, or plasmid-encoded or stably derepressed, chromosomally encoded AmpC ␤-lactamases, thereby limiting its potential utility against MBL-producing isolates that also contain one or more of these serine ␤-lactamases (8). Avibactam is a non-␤-lactam ␤-lactamase inhibitor that is active against Ambler class A and C and some class D (OXA-48) enzymes (9, 10). Aztreonam combined with avibactam has demonstrated activity against Enterobacteriaceae that coproduce MBLs and class A or class C ␤-lactamases (11, 12).As part of a global surveillance program, the molecular basis of carbapenem resistance in Gram-negative pathogens was investigated in order to determine the incidence of acquired MBLs and the geographic regions in which these ␤-lactamases are most problematic. This report describes the isolation and regional distribution of MBL-positive Enterobacteriaceae and Pseudomonas aeruginosa isolates collected from 2012 to 2014. MATERIALS AND METHODSNonduplicate bacterial isolates from intra-abdominal, urinary tract, skin and soft tissue, lower respiratory tract, and bloodstream infections were collected from 202 sites in 40 countries located in five major geographic regions (Asia-Pacific, Europe, Latin America, the Middle East-Africa, and North America). A predefined number of isolates of selected bacterial species were collected from each site regardless of antibiotic susceptibility. Organism collection, transport, confirmation of organism identification, susceptibility testing, molecular characterization, quality assurance of

show abstract

Section: Discussionsupporting

confidence: 65%

Multiyear, Multinational Survey of the Incidence and Global Distribution of Metallo-β-Lactamase-Producing Enterobacteriaceae and Pseudomonas aeruginosa

Kazmierczak¹,

Rabine²,

Hackel³

et al. 2016

Antimicrob Agents Chemother

189

117

View full text Add to dashboard Cite

show abstract

“…and ) the bla VIM‐4 gene was identified as part of a class I integron (Table 1). The integron was similar to other bla VIM‐4 ‐containing integrons identified in various Enterobacteriaceae isolates in Italy, Russia, Tunisia and Greece (Table 1) [4,8,10,11]. However, unlike in the Italian isolate VA‐416/02 [11], in ABC104 the conserved 3′ end of the class 1 integron was identified downstream of the IS Pa21 (GenBank accession number ).…”

Section: Genotypic Characteristics Of Vim‐4 Producing Enterobacteriamentioning

confidence: 55%

VIM-4 carbapenemase-producing Enterobacter cloacae in the United Arab Emirates

Sonnevend

Ghazawi

Yahfoufi

et al. 2012

Clinical Microbiology and Infection

View full text Add to dashboard Cite

Screening 34 carbapenem non-susceptible Enterobacteriaceae recovered in Abu Dhabi hospitals identified an Enterobacter cloacae strain carrying bla(VIM-4) , bla(CMY-4) and bla(CTX-M-15) . It was isolated from the urine of an Egyptian patient repeatedly hospitalized and treated with broad-spectrum antibiotics, including carbapenems, in the United Arab Emirates. The bla(VIM-4) coding class I integron, highly similar to In416, was carried on a 175-kilobase non-conjugative incA/C type plasmid also hybridizing with the bla(CMY-4) probe. This is the first detailed report on the isolation of a Verona integron-encoded metallo-β-lactamase (VIM) -producing enteric bacterium in the Arabian Peninsula with characteristics suggestive of spreading from the Mediterranean region.

show abstract

“…Carbapenem resistance in Enterobacteriaceae is a new emerging problem caused primarily by plasmid-encoded carbapenemases (Table 2) [25,35,36,37,38,39,40]. To date, these enzymes are mainly found in nosocomial isolates of Klebsiella pneumoniae and E. coli [36,38].…”

Section: Mechanisms Of Resistancementioning

confidence: 99%

“…To date, these enzymes are mainly found in nosocomial isolates of Klebsiella pneumoniae and E. coli [36,38]. In Europe, carbapenemases-producing isolates are differently distributed among countries [35,36,37,38,39,40]. Furthermore, the prevalence of these strains appears to follow a north-south distribution [36,40].…”

Section: Mechanisms Of Resistancementioning

confidence: 99%

“…Furthermore, multiresistant strains were also isolated, except in Bosnia and Herzegovina, probably due to limited surveillance data available for these countries [57]. ESBL-positive E. coli isolates resistant to quinolones and aminoglycosides were detected in Russia [37,45,56]. Resistance rates to ciprofloxacin and nalidixic acid in isolates were 12.9% and 17.2% respectively.…”

Section: Epidemiology Of Resistancementioning

confidence: 99%

See 1 more Smart Citation

Escherichia coli in Europe: An Overview

Allocati

Masulli

Alexeyev

et al. 2013

IJERPH

376

259

View full text Add to dashboard Cite

Escherichia coli remains one of the most frequent causes of several common bacterial infections in humans and animals. E. coli is the prominent cause of enteritis, urinary tract infection, septicaemia and other clinical infections, such as neonatal meningitis. E. coli is also prominently associated with diarrhoea in pet and farm animals. The therapeutic treatment of E. coli infections is threatened by the emergence of antimicrobial resistance. The prevalence of multidrug-resistant E. coli strains is increasing worldwide principally due to the spread of mobile genetic elements, such as plasmids. The rise of multidrug-resistant strains of E. coli also occurs in Europe. Therefore, the spread of resistance in E. coli is an increasing public health concern in European countries. This paper summarizes the current status of E. coli strains clinically relevant in European countries. Furthermore, therapeutic interventions and strategies to prevent and control infections are presented and discussed. The article also provides an overview of the current knowledge concerning promising alternative therapies against E. coli diseases.

show abstract

First detection of VIM-4 metallo-β-lactamase-producing Escherichia coli in Russia

Cited by 23 publications

References 27 publications

Multiyear, Multinational Survey of the Incidence and Global Distribution of Metallo-β-Lactamase-Producing Enterobacteriaceae and Pseudomonas aeruginosa

Multiyear, Multinational Survey of the Incidence and Global Distribution of Metallo-β-Lactamase-Producing Enterobacteriaceae and Pseudomonas aeruginosa

VIM-4 carbapenemase-producing Enterobacter cloacae in the United Arab Emirates

Escherichia coli in Europe: An Overview

Contact Info

Product

Resources

About